Brief: Ignite Proteomics Announces 10,000-Patient Oncology Registry For Therapy Selection
08/06/2026 13:41
BRIEF-Ignite Proteomics Announces 10,000-Patient Oncology Registry For Therapy Selection June 8 (Reuters) - Aditxt Inc ADTX.O:
IGNITE PROTEOMICS ANNOUNCES PROSPECTIVE 10,000-PATIENT ONCOLOGY REGISTRY TO EVALUATE FUNCTIONAL PROTEOMICS IN CANCER THERAPY SELECTION
IGNITE PROTEOMICS - REGISTRY EXPECTED TO GENERATE ESTIMATED $13 MILLION FOR IGNITE
IGNITE PROTEOMICS - ENROLLMENT FOR REGISTRY EXPECTED TO BEGIN IN FALL 2026
Source text: ID:nBw9fQ3fMa
Further company coverage: ADTX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Aditxt
See all newsBrief: Ignite Proteomics Announces 10,000-Patient Oncology Registry For Therapy Selection
Brief: Aditxt Appoints Jeffrey M. Busch As Interim CEO; Founder And Former CEO Of $1B NYSE Enterprise Which Delivered ~8.5% Dividends To Shareholders
NASDAQ TRADE HALT REASON NOT AVAILABLE AT 03:58 AM
NASDAQ TRADE HALT HALT NEWS PENDING AT 03:28 AM
NASDAQ TRADE HALT HALT NEWS PENDING AT 03:28 AM